CDNA
Price
$13.66
Change
+$0.55 (+4.20%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
727.08M
61 days until earnings call
HBIO
Price
$0.50
Change
-$0.02 (-3.85%)
Updated
Aug 29, 04:58 PM (EDT)
Capitalization
23.17M
69 days until earnings call
Interact to see
Advertisement

CDNA vs HBIO

Header iconCDNA vs HBIO Comparison
Open Charts CDNA vs HBIOBanner chart's image
CareDx
Price$13.66
Change+$0.55 (+4.20%)
Volume$34.93K
Capitalization727.08M
Harvard Bioscience
Price$0.50
Change-$0.02 (-3.85%)
Volume$200
Capitalization23.17M
CDNA vs HBIO Comparison Chart in %
Loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDNA vs. HBIO commentary
Aug 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDNA is a StrongBuy and HBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 30, 2025
Stock price -- (CDNA: $13.66 vs. HBIO: $0.52)
Brand notoriety: CDNA and HBIO are both not notable
CDNA represents the Medical Specialties, while HBIO is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CDNA: 118% vs. HBIO: 39%
Market capitalization -- CDNA: $727.08M vs. HBIO: $23.17M
CDNA [@Medical Specialties] is valued at $727.08M. HBIO’s [@Pharmaceuticals: Other] market capitalization is $23.17M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $169.67B to $0. The average market capitalization across the [@Medical Specialties] industry is $10.55B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $10.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDNA’s FA Score shows that 0 FA rating(s) are green whileHBIO’s FA Score has 0 green FA rating(s).

  • CDNA’s FA Score: 0 green, 5 red.
  • HBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, both CDNA and HBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDNA’s TA Score shows that 4 TA indicator(s) are bullish while HBIO’s TA Score has 5 bullish TA indicator(s).

  • CDNA’s TA Score: 4 bullish, 3 bearish.
  • HBIO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both CDNA and HBIO are a good buy in the short-term.

Price Growth

CDNA (@Medical Specialties) experienced а +5.32% price change this week, while HBIO (@Pharmaceuticals: Other) price change was +9.26% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.46%. For the same industry, the average monthly price growth was +7.37%, and the average quarterly price growth was +8.13%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.47%. For the same industry, the average monthly price growth was +5.74%, and the average quarterly price growth was +15.16%.

Reported Earning Dates

CDNA is expected to report earnings on Oct 30, 2025.

HBIO is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Medical Specialties (-0.46% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Pharmaceuticals: Other (+0.47% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDNA($727M) has a higher market cap than HBIO($23.2M). CDNA YTD gains are higher at: -36.198 vs. HBIO (-75.346). CDNA has higher annual earnings (EBITDA): -23.07M vs. HBIO (-46.8M). CDNA has more cash in the bank: 186M vs. HBIO (7.44M). CDNA has less debt than HBIO: CDNA (29.1M) vs HBIO (43.3M). CDNA has higher revenues than HBIO: CDNA (341M) vs HBIO (88.8M).
CDNAHBIOCDNA / HBIO
Capitalization727M23.2M3,134%
EBITDA-23.07M-46.8M49%
Gain YTD-36.198-75.34648%
P/E Ratio12.49N/A-
Revenue341M88.8M384%
Total Cash186M7.44M2,499%
Total Debt29.1M43.3M67%
FUNDAMENTALS RATINGS
CDNA vs HBIO: Fundamental Ratings
CDNA
HBIO
OUTLOOK RATING
1..100
1514
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6565
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDNA's Valuation (93) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that CDNA’s stock grew similarly to HBIO’s over the last 12 months.

CDNA's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that CDNA’s stock grew similarly to HBIO’s over the last 12 months.

CDNA's SMR Rating (100) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that CDNA’s stock grew similarly to HBIO’s over the last 12 months.

CDNA's Price Growth Rating (65) in the Medical Specialties industry is in the same range as HBIO (65) in the Biotechnology industry. This means that CDNA’s stock grew similarly to HBIO’s over the last 12 months.

CDNA's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that CDNA’s stock grew similarly to HBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDNAHBIO
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 3 days ago
64%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 4 days ago
73%
Declines
ODDS (%)
Bearish Trend 16 days ago
88%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OMSNX28.84N/A
N/A
Invesco Main Street All Cap R
RYMDX138.24N/A
N/A
Rydex Mid-Cap 1.5x Strategy H
PIREX28.68N/A
N/A
Principal Real Estate Securities Inst
PSSRX25.24N/A
N/A
PGIM Jennison Financial Services R
BAFGX18.73N/A
N/A
Brown Advisory Growth Equity Inst

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
-2.60%
IRMD - HBIO
46%
Loosely correlated
-1.12%
A - HBIO
37%
Loosely correlated
+5.28%
RVTY - HBIO
36%
Loosely correlated
+0.72%
MTD - HBIO
35%
Loosely correlated
-0.17%
NEOG - HBIO
34%
Loosely correlated
+0.17%
More